Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03566199 · ClinicalTrials.gov registry record · Phase 1
MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
A Phase 1 study, sponsored by Sabine Mueller, MD, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03566199 is a Phase 1 study that has completed, run by Sabine Mueller, MD, PhD. The registered enrollment target is 7 participants.
The verdict
NCT03566199, a Phase 1 study, has completed, sponsored by Sabine Mueller, MD, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Panobinostat Nanoparticle Formulation MTX110
- DRUG Convection-Enhanced Delivery (CED)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03566199
The ClinicalTrials.gov registry entry for NCT03566199 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Panobinostat Nanoparticle Formulation MTX110 is the first listed.
NCT03566199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03566199 about?
NCT03566199 is a clinical study titled "MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma". This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by blocking some of the enzymes need...
What is the current status of trial NCT03566199?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2018-05-22. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03566199?
The interventions under investigation include: Panobinostat Nanoparticle Formulation MTX110 (DRUG), Convection-Enhanced Delivery (CED) (DRUG).
Who is sponsoring clinical trial NCT03566199?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.